An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant. MM and other hematologic malignancies express ubiquitous constitutive proteasome...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Downey-Kopyscinski, Sondra, Daily, Ellen W., Gautier, Marc, Bhatt, Ananta, Florea, Bogdan I., Mitsiades, Constantine S., Richardson, Paul G., Driessen, Christoph, Overkleeft, Herman S., Kisselev, Alexei F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2018
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177641/
https://ncbi.nlm.nih.gov/pubmed/30266819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016360
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller